Lupin is lined up to copy 5 of the blockbuster drugs on this tracker, which earned $39.2B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Lupin's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved Jan 2025 | $7.7B |
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Xtandi | Astellas / Pfizer | Generic | 2027 | FDA tentative approval | ≈$6.0B |
| Descovy | Gilead | Generic | 2031 | Settled 2022 | $2.8B |
| Biktarvy | Gilead | Generic | 2036 | Settled Oct 2025 | $14.3B |
Company facts: Screener. Each drug page lists sources for these entries. Brand sales show the size of the market, not Lupin's share of it.